Protein Science CSH PROT
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by VAN-DEN-AKKER, F.
Right arrow Articles by HOL, WGJ.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by VAN-DEN-AKKER, F.
Right arrow Articles by HOL, WGJ.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Protein Science, Vol 6, Issue 12 2650-2654, Copyright © 1997 by Cold Spring Harbor Laboratory Press


FOR THE RECORD

Crystal structure of a non-toxic mutant of heat-labile enterotoxin, which is a potent mucosal adjuvant

F. VAN-DEN-AKKER, M. PIZZA, R. RAPPUOLI and WGJ. HOL
Department of Biochemistry, University of Washington, Seattle, WA 98195-7420 Department of Biological Structure, University of Washington, Seattle, WA 98195-7420

Two closely related bacterial toxins, heat-labile enterotoxin (LT-I) and cholera toxin (CT), not only invoke a toxic activity that affects many victims worldwide but also contain a beneficial mucosal adjuvant activity that significantly enhances the potency of vaccines in general. For the purpose of vaccine design it is most interesting that the undesirable toxic activity of these toxins can be eliminated by the single-site mutation Ser63Lys in the A subunit while the mucosal adjuvant activity is still present. The crystal structure of the Ser63Lys mutant of LT-I is determined at 2.0 A resolution. Its structure appears to be essentially the same as the wild-type LT-I structure. The substitution Ser63Lys was designed, based on the wild-type LT-I crystal structure, to decrease toxicity by interfering with NAD binding and/or catalysis. In the mutant crystal structure, the newly introduced lysine side chain is indeed positioned such that it could potentially obstruct the productive binding mode of the substrate NAD while at the same time its positive charge could possibly interfere with the critical function of nearby charged groups in the active site of LT-I. The fact that the Ser63Lys mutant of LT-I does not disrupt the wild-type LT-I structure makes the non-toxic mutant potentially suitable, from a structural point of view, to be used as a vaccine to prevent enterotoxigenic E. coli infections. The structural similarity of mutant and wild-type toxin might also be the reason why the inactive Ser63Lys variant retains its adjuvant activity.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
J. Sanchez, G. Wallerstrom, M. Fredriksson, J. Angstrom, and J. Holmgren
Detoxification of Cholera Toxin without Removal of Its Immunoadjuvanticity by the Addition of (STa-related) Peptides to the Catalytic Subunit. A POTENTIAL NEW STRATEGY TO GENERATE IMMUNOSTIMULANTS FOR VACCINATION
J. Biol. Chem., August 30, 2002; 277(36): 33369 - 33377.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. P. Simmons, T. Hussell, T. Sparer, G. Walzl, P. Openshaw, and G. Dougan
Mucosal Delivery of a Respiratory Syncytial Virus CTL Peptide with Enterotoxin-Based Adjuvants Elicits Protective, Immunopathogenic, and Immunoregulatory Antiviral CD8+ T Cell Responses
J. Immunol., January 15, 2001; 166(2): 1106 - 1113.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. Loregian, E. Papini, B. Satin, H. S. Marsden, T. R. Hirst, and G. Palu
Intranuclear delivery of an antiviral peptide mediated by the B subunit of Escherichia coli heat-labile enterotoxin
PNAS, April 27, 1999; 96(9): 5221 - 5226.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
L. A. Stevens, J. Moss, M. Vaughan, M. Pizza, and R. Rappuoli
Effects of Site-Directed Mutagenesis of Escherichia coli Heat-Labile Enterotoxin on ADP-Ribosyltransferase Activity and Interaction with ADP-Ribosylation Factors
Infect. Immun., January 1, 1999; 67(1): 259 - 265.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by The Protein Society.